期刊文献+

健脾化痰方联合托烷司琼治疗乳腺癌放化疗后呕吐疗效观察 被引量:1

下载PDF
导出
摘要 目的:观察健脾化痰方联合托烷司琼治疗乳腺癌放化疗后呕吐的效果。方法:96例随机均分为两组各48例,两组均用托烷司琼治疗,研究组加用健脾化痰方治疗。结果:两组RBC、WBC、PLT和LTR%均明显低于治疗前(P<0.05),ALT、AST均明显高于治疗前(P<0.05),而两组差异显著(P<0.05)。两组各症状评分明显降低(P<0.05),而研究组降低幅度更大(P<0.05)。总有效率分别为95.83%、81.25%,两组总有效率比较差异无统计学意义(P<0.05)。结论:健脾化痰方联合托烷司琼治疗乳腺癌放化疗所致呕吐可明显改善症状,提高治疗效果。
作者 张艳
出处 《实用中医药杂志》 2018年第5期561-562,共2页 Journal of Practical Traditional Chinese Medicine
  • 相关文献

参考文献3

二级参考文献33

  • 1石书芳.陈熠运用调神解郁法治疗乳腺癌术后临床分析[J].四川中医,2013,31(8):12-14. 被引量:3
  • 2Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer[J]. N Engl J Med,2010,363(20) :1938-1948.
  • 3Carey LA,Dees EC,Sawyer L, et al. The triple negative para-dox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res,2007,13(8) :2329-2334.
  • 4Iwata H, Sato N, Masuda N, et al. Docetaxel followed by flu-orouracil/epirubicin/cyclophosphamide as neoadjuvant chemo-therapy for patients with primary breast cancer[J]. Jpn J ClinOncol,2011,41(7) :867-875.
  • 5Warm M, Kates R, Grobe-Onnebrink E, et al. Impact of tumorbiology,particularly triple-negative status,on response to preop-erative sequential, dose-dense epirubicin, cyclophosphamide fol-lowed by docetaxel in breast cancer[J]. Anti cancer Res, 2010,30(10):4251-4259.
  • 6Torrisi R.Balduzzi A’Ghisini R, et al. Tailored preoperative treat-ment of locally advanced triple negative (hormone receptor negativeand Her-2 negative) breast cancer with epirubicin, cisplatin.and infu-sional fluorouracil followed by weekly paclitaxel [J]. Cancer Che-mother Pharmacol,2008,62(4) :667-672.
  • 7Eisenhauer EA, Therasse P, Bogaerts J, et al. New response e-valuation criteria in solid tumours: revised RECIST guideline(version 1. 1) [J]. Eur J Cancer,2009,45(2) :228-247.
  • 8Huober J,von Minckwitz G,Denkert C et al. Effect of neoadju-vant anthracycline taxane-based chemotherapy in different bio-logical breast cancer phenotypes : overall results from the Gepar-Trio study[J]. Breast Cancer Res Treat,2010,124(1) : 133-140.
  • 9Wu J, Li S’Jia W, et al. Response and prognosis of taxanes andanthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer[J]. J Cancer Res Clin Oncol, 2011, 137(10)=1505-1510.
  • 10Liedtke C,Mazouni C,Hess KR,et al. Response to neoadjuvanttherapy and long-term survival in patients with triple-negativebreast cancer[J]. J Clin Oncol,2008’26(8) : 1275-1281.

共引文献124

同被引文献40

引证文献1

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部